Stoke Therapeutics (STOK) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
The meeting was called to order at 9:00 A.M. Eastern Time on June 3rd, 2026, with a virtual format to increase inclusivity and participation.
Board members, corporate officers, legal counsel, and independent accountants were introduced.
The agenda included formal business matters, voting on proposals, and a Q&A session at the end.
Corporate governance
The record date for voting was set as April 7th, 2026, with notice and proxy materials mailed to eligible stockholders.
A quorum was established with 88.6% of shares represented, allowing the meeting to proceed.
Overview of voting outcomes
Three proposals were presented: election of directors, ratification of the accounting firm, and advisory approval of executive compensation.
G. Clare Kahn, Adrian Krainer, and Julie Anne Smith were elected as Class I directors for three-year terms.
Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31st, 2026.
Executive compensation was approved on an advisory basis by a majority vote.
Latest events from Stoke Therapeutics
- Durable efficacy and cognitive gains position zorevunersen for a focused U.S. launch by 2028.STOK
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Lead therapy for Dravet shows durable efficacy, with phase III data and NDA submission expected in 2027.STOK
Jefferies Global Healthcare Conference 20264 Jun 2026 - Four-year data confirm durable efficacy, with $411M cash runway and Phase 3 on track.STOK
Q1 202611 May 2026 - Phase III Dravet study nears full enrollment, with strong efficacy and market positioning.STOK
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.STOK
Proxy filing23 Apr 2026 - Board recommends approval of director elections, auditor, and executive pay; strong governance and oversight.STOK
Proxy filing23 Apr 2026 - Zorevunersen shows sustained efficacy and cognitive gains, with phase III readout expected mid-2027.STOK
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Four-year data show durable seizure reduction and cognitive gains, with phase 3 readout in 2027.STOK
Guggenheim Securities Emerging Outlook: Biotech Summit 202610 Apr 2026 - 2025 revenue jumped to $184.4M, net loss narrowed, and cash runway extends into 2028.STOK
Q4 202516 Mar 2026